EM2603B "PCSK9 Inhibition: From Variant Discovery to Post-Transcriptional Control" (IM GR-03.06.26)

Purpose and Overview

objectives: 
- understand the effects of PCSK9 inhibitors on lipoproteins and clinical outcomes
- appraise the landscape of existing and upcoming PCSK9 inhibition strategies

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • understand the effects of PCSK9 inhibition on lipoproteins and cardiovascular outcomes in primary and secondary prevention
  • Describing the existing and upcoming pharmacologic options for inhibiting PCSK9
  • Assess the benefits and risks of PCSK9 inhibition
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
03/06/2026
Course expires: 
06/06/2026
Cost:
$0.00
Rating: 
0

Dr. P. Gabriel Steg

P. Gabriel Steg, M.D.
Professor, Université Paris-Cité
Chief, Department of Cardiology, Hôpital Bichat
Vice-President, Assistance Publique - Hôpitaux de Paris

Available Credit

  • 1.00 AMA

Price

Cost:
$0.00
Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome